Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Alkermes ( ($ALKS) ) has shared an announcement. On November 18, 2025, Alkermes plc and Avadel Pharmaceuticals plc amended their transaction agreem...

Alkermes Increases Offer for Avadel Acquisition

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Alkerme...

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Alkermes (ALKS)

Jefferies analyst Akash Tewari maintained a Buy rating on Alkermes today and set a price target of $58.00. Tewari covers the Healthcare sector, foc...

Jefferies Keeps Their Buy Rating on Alkermes (ALKS)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Alkermes on November 10 and set a price target of $47.00. The company’s shares close...

Alkermes (ALKS) Gets a Buy from RBC Capital

Roth MKM analyst initiated coverage with a Buy rating on Alkermes yesterday and set a price target of $50.00. In addition to Roth MKM, Alkermes als...

Alkermes (ALKS) Receives a New Rating from Roth MKM

In a report released yesterday, Joon Lee from Truist Financial initiated coverage with a Buy rating on Alkermes and a price target of $50.00. The c...

Alkermes (ALKS) Receives a New Rating from a Top Analyst

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes, with a price target of $42.00. Matteis covers th...

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)

In a report released on October 28, Leonid Timashev from RBC Capital maintained a Buy rating on Alkermes, with a price target of $47.00. The compan...

RBC Capital Keeps Their Buy Rating on Alkermes (ALKS)

Alkermes plc ( ($ALKS) ) has released its Q3 earnings. Here is a breakdown of the information Alkermes plc presented to its investors. Alkermes plc...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$1.07	Growth Streak	1 years
Ex-Dividend	Invalid Date	Pay Date	11/15/2023
Frequency	NA	Quarterly Est	$0.27

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALKS	$28.99	+2.80%	1.60M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALKS	$28.99	+2.8%	1.60M
3
4
5
6

ALKS

ALKS

Dividend Overview

Recent Dividend History

Get Alkermes plc Data in Excel

Get Alkermes plc Data in Excel